Evaluation of the antigenicity of universal epitopes from PvDBPII in individuals exposed to Plasmodium vivax malaria

Microbes and Infection

Volumn 12, Issue 14-15, 2010, Pages 1188-1197

  Martinez, Paola ^a,b   Lopez, Carolina ^a,b,c   Saravia, Carolina ^a   Vanegas, Magnolia ^a,b   Patarroyo, Manuel A ^a,b  

^a FUNDACIÓN INSTITUTO DE INMUNOLOGÍA DE COLOMBIA FIDIC   (Colombia)

^b UNIVERSIDAD DEL ROSARIO   (Colombia)

^c UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Cell proliferation; Cytokines; Duffy binding protein; Peptide vaccines; Plasmodium vivax

Indexed keywords

DUFFY BINDING PROTEIN; EPITOPE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 6; PEPTIDE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ALLELE; ANTIGENICITY; ARTICLE; BINDING AFFINITY; CELL ISOLATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; PROTEIN BINDING;

ADOLESCENT; ADULT; AGED; ANTIGENS, PROTOZOAN; CELL PROLIFERATION; EPITOPES; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALARIA, VIVAX; MALE; MIDDLE AGED; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECEPTORS, CELL SURFACE; YOUNG ADULT;

PLASMODIUM VIVAX;

EID: 78649826770     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2010.08.007     Document Type: Article

References (50)

1. Hay S.I., Guerra C.A., Tatem A.J., Noor A.M., Snow R.W. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect. Dis. 2004, 4:327-336.
2. Nih The Jordan Report: Accelerated Development of Vaccine 2007, National Institutes of Health, p. 164.
3. Hommel M., David P.H., Oligino L.D. Surface alterations of erythrocytes in Plasmodium falciparum malaria. Antigenic variation, antigenic diversity, and the role of the spleen. J. Exp. Med. 1983, 157:1137-1148.
4. Rotman H.L., Daly T.M., Long C.A. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge. Exp. Parasitol. 1999, 91:78-85.
5. Patarroyo M.E., Vinasco J., Amador R., Espejo F., Silva Y., Moreno A., Rojas M., Mora A.L., Salcedo M., Valero V., et al. Genetic control of the immune response to a synthetic vaccine against Plasmodium falciparum. Parasite Immunol. 1991, 13:509-516.
6. Doolan D.L., Southwood S., Chesnut R., Appella E., Gomez E., Richards A., Higashimoto Y.I., Maewal A., Sidney J., Gramzinski R.A., Mason C., Koech D., Hoffman S.L., Sette A. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J. Immunol. 2000, 165:1123-1137.
7. Calvo-Calle J.M., Hammer J., Sinigaglia F., Clavijo P., Moya-Castro Z.R., Nardin E.H. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J. Immunol. 1997, 159:1362-1373.
8. Nardin E.H., Calvo-Calle J.M., Oliveira G.A., Nussenzweig R.S., Schneider M., Tiercy J.M., Loutan L., Hochstrasser D., Rose K. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J. Immunol. 2001, 166:481-489.
9. WHO World Malaria Report 2005, World Health Organization, Switzerland, p. 330.
10. Mueller I., Galinski M.R., Baird J.K., Carlton J.M., Kochar D.K., Alonso P.L., del Portillo H.A. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect. Dis. 2009, 9:555-566.
11. Higgs E.S., Sina B. Plasmodium vivax vaccine research: steps in the right direction. Am. J. Trop. Med. Hyg. 2005, 73:1-2.
12. Suh K.N., Kain K.C., Keystone J.S. Malaria. Cmaj 2004, 170:1693-1702.
13. Miller L.H., Baruch D.I., Marsh K., Doumbo O.K. The pathogenic basis of malaria. Nature 2002, 415:673-679.
14. Miller L.H., Mason S.J., Clyde D.F., McGinniss M.H. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N. Engl. J. Med. 1976, 295:302-304.
15. Adams J.H., Sim B.K., Dolan S.A., Fang X., Kaslow D.C., Miller L.H. A family of erythrocyte binding proteins of malaria parasites. Proc. Natl. Acad. Sci. U S A 1992, 89:7085-7089.
16. Kasehagen L.J., Mueller I., Kiniboro B., Bockarie M.J., Reeder J.C., Kazura J.W., Kastens W., McNamara D.T., King C.H., Whalen C.C., Zimmerman P.A. Reduced Plasmodium vivax erythrocyte infection in PNG Duffy-negative heterozygotes. PLoS One 2007, 2:e336.
17. Chitnis C.E., Miller L.H. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J. Exp. Med. 1994, 180:497-506.
18. Ampudia E., Patarroyo M.A., Patarroyo M.E., Murillo L.A. Genetic polymorphism of the Duffy receptor binding domain of Plasmodium vivax in Colombian wild isolates. Mol. Biochem. Parasitol. 1996, 78:269-272.
19. Tsuboi T., Kappe S.H., al-Yaman F., Prickett M.D., Alpers M., Adams J.H. Natural variation within the principal adhesion domain of the Plasmodium vivax duffy binding protein. Infect. Immun. 1994, 62:5581-5586.
20. Ceravolo I.P., Souza-Silva F.A., Fontes C.J., Braga E.M., Madureira A.P., Krettli A.U., Souza J.M., Brito C.F., Adams J.H., Carvalho L.H. Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmission. Scand. J. Immunol. 2008, 67:270-278.
21. Michon P., Fraser T., Adams J.H. Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. Infect. Immun. 2000, 68:3164-3171.
22. Grimberg B.T., Udomsangpetch R., Xainli J., McHenry A., Panichakul T., Sattabongkot J., Cui L., Bockarie M., Chitnis C., Adams J., Zimmerman P.A., King C.L. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med. 2007, 4:e337.
23. Fraser T., Michon P., Barnwell J.W., Noe A.R., Al-Yaman F., Kaslow D.C., Adams J.H. Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein. Infect. Immun. 1997, 65:2772-2777.
24. Xainli J., Cole-Tobian J.L., Baisor M., Kastens W., Bockarie M., Yazdani S.S., Chitnis C.E., Adams J.H., King C.L. Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. Infect. Immun. 2003, 71:2508-2515.
25. Ocampo M., Vera R., Eduardo Rodriguez L., Curtidor H., Urquiza M., Suarez J., Garcia J., Puentes A., Lopez R., Trujillo M., Torres E., Patarroyo M.E. Plasmodium vivax Duffy binding protein peptides specifically bind to reticulocytes. Peptides 2002, 23:13-22.
26. Saravia C., Martinez P., Granados D.S., Lopez C., Reyes C., Patarroyo M.A. Identification and evaluation of universal epitopes in Plasmodium vivax Duffy binding protein. Biochem. Biophys. Res. Commun. 2008, 377:1279-1283.
27. Houghten R.A. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc. Natl. Acad. Sci. U S A 1985, 82:5131-5135.
28. Pico de Coana Y., Rodriguez J., Guerrero E., Barrero C., Rodriguez R., Mendoza M., Patarroyo M.A. A highly infective Plasmodium vivax strain adapted to Aotus monkeys: quantitative haematological and molecular determinations useful for P. vivax malaria vaccine development. Vaccine 2003, 21:3930-3937.
29. Andrysiak P.M., Collins W.E., Campbell G.H. Concentration of Plasmodium ovale-and Plasmodium vivax-infected erythrocytes from nonhuman primate blood using Percoll gradients. Am. J. Trop. Med. Hyg. 1986, 35:251-254.
30. Olerup O., Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992, 39:225-235.
31. Rojas O.L., Rojas-Villarraga A., Cruz-Tapias P., Sanchez J.L., Suarez-Escudero J.C., Patarroyo M.A., Anaya J.M. HLA class II polymorphism in Latin American patients with multiple sclerosis. Autoimmunity reviews 2010, 9:407-413.
32. Southwood S., Sidney J., Kondo A., del Guercio M.F., Appella E., Hoffman S., Kubo R.T., Chesnut R.W., Grey H.M., Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 1998, 160:3363-3373.
33. Migot-Nabias F., Luty A.J., Ringwald P., Vaillant M., Dubois B., Renaut A., Mayombo R.J., Minh T.N., Fievet N., Mbessi J.R., Millet P., Deloron P. Immune responses against Plasmodium falciparum asexual blood-stage antigens and disease susceptibility in Gabonese and Cameroonian children. Am. J. Trop. Med. Hyg. 1999, 61:488-494.
34. Rhee M.S., Akanmori B.D., Waterfall M., Riley E.M. Changes in cytokine production associated with acquired immunity to Plasmodium falciparum malaria. Clin. Exp. Immunol. 2001, 126:503-510.
35. Winkler S., Willheim M., Baier K., Graninger W., Kremsner P.G. Frequency of cytokine-producing CD4-CD8- peripheral blood mononuclear cells in patients with Plasmodium falciparum malaria. Eur. Cytokine Netw. 1999, 10:155-160.
36. Chitnis C.E., Chaudhuri A., Horuk R., Pogo A.O., Miller L.H. The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes. J. Exp. Med. 1996, 184:1531-1536.
37. Ranjan A., Chitnis C.E. Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins. Proc. Natl. Acad. Sci. U S A 1999, 96:14067-14072.
38. Cole-Tobian J.L., Michon P., Biasor M., Richards J.S., Beeson J.G., Mueller I., King C.L. Strain-specific Duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children. Infect. Immun. 2009, 77:4009-4017.
39. Chootong P., Ntumngia F.B., Vanbuskirk K.M., Xainli J., Cole-Tobian J.L., Campbell C.O., Fraser T.S., King C.L., Adams J.H. Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. Infect. Immun. 2010, 78:1089-1095.
40. Michon P.A., Arevalo-Herrera M., Fraser T., Herrera S., Adams J.H. Serologic responses to recombinant Plasmodium vivax Duffy binding protein in a Colombian village. Am. J. Trop. Med. Hyg. 1998, 59:597-599.
41. Singotamu L., Hemalatha R., Madhusudhanachary P., Seshacharyulu M. Cytokines and micronutrients in Plasmodium vivax infection. J. Med. Sci. 2006, 6:962-967.
42. Robinson L.J., D'Ombrain M.C., Stanisic D.I., Taraika J., Bernard N., Richards J.S., Beeson J.G., Tavul L., Michon P., Mueller I., Schofield L. Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea. Infect. Immun. 2009, 77:3033-3043.
43. Lyke K.E., Burges R., Cissoko Y., Sangare L., Dao M., Diarra I., Kone A., Harley R., Plowe C.V., Doumbo O.K., Sztein M.B. Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect. Immun. 2004, 72:5630-5637.
44. Seth R.K., Bhat A.A., Rao D.N., Biswas S. Acquired immune response to defined Plasmodium vivax antigens in individuals residing in northern India. Microbes Infect 2010, 12:199-206.
45. Amante F.H., Crewther P.E., Anders R.F., Good M.F. A cryptic T cell epitope on the apical membrane antigen 1 of Plasmodium chabaudi adami can prime for an anamnestic antibody response: implications for malaria vaccine design. J. Immunol. 1997, 159:5535-5544.
46. Patarroyo M.E., Cifuentes G., Bermudez A., Patarroyo M.A. Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines. J. Cell Mol. Med. 2008, 12:1915-1935.
47. Patarroyo M.E., Cifuentes G., Martinez N.L., Patarroyo M.A. Atomic fidelity of subunit-based chemically-synthesized antimalarial vaccine components. Prog Biophys Mol Biol. 2010, 102:38-44.
48. Patarroyo M.E., Patarroyo M.A. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines. Acc. Chem. Res. 2008, 41:377-386.
49. Xainli J., Baisor M., Kastens W., Bockarie M., Adams J.H., King C.L. Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. J. Immunol. 2002, 169:3200-3207.
50. McHenry A.M., Barnwell J.W., Adams J.H. Plasmodium vivax DBP binding to Aotus nancymaae erythrocytes is Duffy antigen dependent. J. Parasitol. 2010, 96:225-227.